Paper11479214
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
Oesterreich S and 7 others. Cancer Res, 2001. Cited by 138 papers, by iCite.
Cite this record
ConductScience Library. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Papers, record 11479214. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11479214
- Cell line
- MCF-7/C4-122 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Source Cell lines
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Estradiol | Major topic |
| Insulin-Like Growth Factor I | Major topic |
| Phosphoproteins | Major topic |
| Receptor, IGF Type 1 | Major topic |
| Receptors, Estrogen | Major topic |
| Signal Transduction | Major topic |
| Cell Division | |
| Cyclin D1 | |
| Estrogen Receptor alpha | |
| Hemagglutinins | |
| Humans | |
| Insulin Receptor Substrate Proteins | |
| Phosphorylation | |
| Transfection | |
| Tumor Cells, Cultured |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA50354 | NCI NIH HHS | United States | R29CA050354 | PubMed and NIH | NIH RePORTER |
| P50 CA58183 | NCI NIH HHS | United States | P50CA058183 | PubMed and NIH | NIH RePORTER |
Cited by55
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39207954 | ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. | Endocrinology | 2024 | https://conductscience.org/library/papers/39207954 | PubMed |
| 37808197 | Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37808197 | PubMed |
| 35784325 | Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases - Why Not This One? | Front Immunol | 2022 | https://conductscience.org/library/papers/35784325 | PubMed |
| 34373577 | RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells. | Oncogene | 2021 | https://conductscience.org/library/papers/34373577 | PubMed |
| 33405908 | A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor α in an MCF-7 Microarray Compendium. | Chem Res Toxicol | 2021 | https://conductscience.org/library/papers/33405908 | PubMed |
| 30229539 | Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. | Horm Cancer | 2018 | https://conductscience.org/library/papers/30229539 | PubMed |
| 30132047 | Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation. | Arch Toxicol | 2018 | https://conductscience.org/library/papers/30132047 | PubMed |
| 29963233 | ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. | Oncotarget | 2018 | https://conductscience.org/library/papers/29963233 | PubMed |
| 29692855 | Exploring the Pharmacological Mechanism of Danzhi Xiaoyao Powder on ER-Positive Breast Cancer by a Network Pharmacology Approach. | Evid Based Complement Alternat Med | 2018 | https://conductscience.org/library/papers/29692855 | PubMed |
| 27527851 | Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/27527851 | PubMed |
| 27446805 | Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways. | Front Oncol | 2016 | https://conductscience.org/library/papers/27446805 | PubMed |
| 27444280 | The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. | Tumour Biol | 2016 | https://conductscience.org/library/papers/27444280 | PubMed |
| 27009360 | Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation. | Sci Rep | 2016 | https://conductscience.org/library/papers/27009360 | PubMed |
| 26113056 | A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. | Horm Cancer | 2015 | https://conductscience.org/library/papers/26113056 | PubMed |
| 25674003 | The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis. | Onco Targets Ther | 2015 | https://conductscience.org/library/papers/25674003 | PubMed |
| 24716121 | Genistein as a Potential Anticancer Agent against Ovarian Cancer. | J Tradit Complement Med | 2012 | https://conductscience.org/library/papers/24716121 | PubMed |
| 24670685 | Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24670685 | PubMed |
| 24601643 | Histone H1 phosphorylation in breast cancer. | J Proteome Res | 2014 | https://conductscience.org/library/papers/24601643 | PubMed |
| 24281069 | RETRACTED: Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. | Cancers (Basel) | 2010 | https://conductscience.org/library/papers/24281069 | PubMed |
| 24119434 | Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. | BMC Cancer | 2013 | https://conductscience.org/library/papers/24119434 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| IGF1 | 3479 | PubTator's text mining | https://conductscience.org/library/genes/3479 | NCBI Gene |
| IGF1R | 3480 | PubTator's text mining | https://conductscience.org/library/genes/3480 | NCBI Gene |
| IRS1 | 3667 | PubTator's text mining | https://conductscience.org/library/genes/3667 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11479214
GET https://conductscience.org/api/papers/v1/11479214/cited_by?page=2